DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Endometriosis
– Pipeline Review, H1 2016” report to their offering.
This report provides comprehensive information on the therapeutic
development for Endometriosis, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for
Endometriosis and special features on late-stage and discontinued
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
- Therapeutics Development
- Pipeline Products for Endometriosis – Overview
- Pipeline Products for Endometriosis – Comparative Analysis
Endometriosis – Therapeutics under Development by Companies
Endometriosis – Therapeutics under Investigation by
- Endometriosis Products Glance
- Late Stage Products
Clinical Stage Products
- Early Stage Products
- Endometriosis – Products under Development by Companies
- Endometriosis – Products under Investigation by Universities/Institutes
Endometriosis – Companies Involved in Therapeutics Development
- AbbVie Inc.
- Addex Therapeutics Ltd
- APAvadis Biotechnologies Srl
Astellas Pharma Inc.
- Bayer AG
- Dongkook Pharmaceutical Co., Ltd.
- ElexoPharm GmbH
- Euroscreen S.A.
- Evotec AG
- Forendo Pharma Limited
- Kissei Pharmaceutical Co., Ltd.
- Lipicard Technologies Limited
- Nippon Shinyaku Co., Ltd.
Orphagen Pharmaceuticals, Inc.
- Philogen S.p.A.
- Repros Therapeutics Inc.
- SK Chemicals Co., Ltd.
Takeda Pharmaceutical Company Limited
- ValiRx Plc
For more information visit http://www.researchandmarkets.com/research/p3fv5t/endometriosis
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Disorders Drugs, Women’s